Eric Sparkes

Medicinal Chemist | Postdoctoral Researcher - School of Chemistry, the University of Sydney | @PayneResearch

[Eric Sparkes @eric_sparkes]

It's all things adamantane in our (@Lambert_Usyd) latest synthetic cannabinoid work, out now in @ACSChemNeurosci!

We synthesised and evaluated a library of adamantane-derived SCRAs, including fluorinated and deuterated analogues 🧪
🧵
https://t.co/yq4EPZPvyZ

[Christophe Stove @christophestove]

🎤 presentation by @AxelleTimmerman @ #TIAFT2024:
"Synthesis and functional evaluation of synthetic cannabinoid receptor agonists related to ADB-HEXINACA"
👉 Fri Sep 6, Session 12
👉 Publ. in May @ACSChemNeurosci: https://t.co/9GY9XbDJLX
👉 🤝 w. @Lambert_Usyd @eric_sparkes
5/11

[Eric Sparkes @eric_sparkes]

Support from @Lambert_Usyd, @SydneyChemistry, @Sydney_Science, Sydney Pharmacy School, @syd_health + ANSTO

[Eric Sparkes @eric_sparkes]

It's all things adamantane in our (@Lambert_Usyd) latest synthetic cannabinoid work, out now in @ACSChemNeurosci!

We synthesised and evaluated a library of adamantane-derived SCRAs, including fluorinated and deuterated analogues 🧪
🧵
https://t.co/yq4EPZPvyZ

[Eric Sparkes @eric_sparkes]

And to @samuel_b_phd, @EA_Cairns and @AdamAmetovski for overseeing this work!

[Christophe Stove @christophestove]

Nice collaborative work (1st paper of @AxelleTimmerman 👏) w. @eric_sparkes & other fantastic @Lambert_Usyd colleagues now out in @ACSChemNeurosci:
Synthesis and Functional Evaluation of Synthetic Cannabinoid Receptor Agonists Related to ADB-HEXINACA
https://t.co/9GY9XbDJLX
🧵 👇

[Eric Sparkes @eric_sparkes]

Thanks to @Lambert_Usyd, @SydneyChemistry, @Sydney_Science, @BrainMind_Usyd, @MQMedicalSchool, and Sydney Pharmacy School for making this work possible.

[Eric Sparkes @eric_sparkes]

More SCRA work from @Lambert_Usyd out now in @rsc_medchem!

We looked at a series of proteinogenic amino acid-derived SCRAs related to MPP-5F-PICA, MMB-5F-PICA, and MDMB-5F-PICA, investigating the role of chirality in CB1 and CB2 receptor activation.

https://t.co/IpUb6vpCRH

[Eric Sparkes @eric_sparkes]

Amazing team includes @JackMarkhamPhD, Rochelle Boyd, @TheCannabisGuyy, Humayra Zaman, Rebecca Gordon, Katelyn Walker, Chianna Dane (@KassiouGroup), @RichardKevinPhD, @MariJSantiago, Dai Hibbs, @samuel_b_phd, @AdamAmetovski, and @EA_Cairns

[Eric Sparkes @eric_sparkes]

Thanks to @Lambert_Usyd @SydneyChemistry @Sydney_Science @ugent and Sydney Pharmacy School for the ongoing support.

[Eric Sparkes @eric_sparkes]

Amazing team includes @AxelleTimmerman @JackMarkhamPhD Rochelle Boyd, Rebecca Gordon, Katelyn Walker, @RichardKevinPhD, Dai Hibbs, @samuel_b_phd, @EA_Cairns, @christophestove, and @AdamAmetovski ✨✨

[Eric Sparkes @eric_sparkes]

In silico evaluation was used to rationalise some structure-activity relationships observed with Induced fit docking performed by @JackMarkhamPhD and Dai Hibbs

[Eric Sparkes @eric_sparkes]

Assessment of βarrestin 2 recruitment was performed by @AxelleTimmerman and @christophestove, with many compounds acting as potent and efficacious agonists at both receptors. Remarkably, many compounds displayed efficacies far above that of CP55,940 at CB1.

[Eric Sparkes @eric_sparkes]

Membrane potential assay work was performed by Rochelle Boyd and @EA_Cairns, and revealed most compounds were potent and efficacious agonists of CB1 and CB2.

[Eric Sparkes @eric_sparkes]

Latest work from @Lambert_Usyd is online in @ACSChemNeurosci!

In another great collaboration with @christophestove et al., we looked at the recently detected synthetic cannabinoid ADB-HEXINACA and related analogues as emerging NPS🧪🔍

https://t.co/Sra7FCUERl